HomeCompareTLTFF vs EQR

TLTFF vs EQR: Dividend Comparison 2026

TLTFF yields 1000.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TLTFF wins by $18844438.64M in total portfolio value
10 years
TLTFF
TLTFF
● Live price
1000.00%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18844438.68M
Annual income
$15,746,803,993,532.36
Full TLTFF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — TLTFF vs EQR

📍 TLTFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTLTFFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TLTFF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TLTFF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TLTFF
Annual income on $10K today (after 15% tax)
$85,000.00/yr
After 10yr DRIP, annual income (after tax)
$13,384,783,394,502.51/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, TLTFF beats the other by $13,384,783,391,255.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TLTFF + EQR for your $10,000?

TLTFF: 50%EQR: 50%
100% EQR50/50100% TLTFF
Portfolio after 10yr
$9422219.36M
Annual income
$7,873,401,998,675.98/yr
Blended yield
83.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TLTFF
No analyst data
Altman Z
-15.2
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TLTFF buys
0
EQR buys
0
No recent congressional trades found for TLTFF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTLTFFEQR
Forward yield1000.00%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$18844438.68M$40.5K
Annual income after 10y$15,746,803,993,532.36$3,819.61
Total dividends collected$18607754.73M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TLTFF vs EQR ($10,000, DRIP)

YearTLTFF PortfolioTLTFF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$110,700$100,000.00$11,248$547.57+$99.5KTLTFF
2$1,153,028$1,034,579.44$12,701$666.53+$1.14MTLTFF
3$11,304,737$10,070,996.94$14,405$814.59+$11.29MTLTFF
4$104,376,400$92,280,331.11$16,413$999.84+$104.36MTLTFF
5$907,965,307$796,282,558.81$18,795$1,232.92+$907.95MTLTFF
6$7,445,190,031$6,473,667,152.78$21,639$1,527.95+$7445.17MTLTFF
7$57,576,798,154$49,610,444,821.11$25,057$1,903.80+$57576.77MTLTFF
8$420,166,535,918$358,559,361,892.40$29,197$2,385.87+$420166.51MTLTFF
9$2,894,985,686,808$2,445,407,493,376.48$34,250$3,008.70+$2894985.65MTLTFF
10$18,844,438,678,417$15,746,803,993,532.36$40,467$3,819.61+$18844438.64MTLTFF

TLTFF vs EQR: Complete Analysis 2026

TLTFFStock

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

Full TLTFF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TLTFF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TLTFF vs SCHDTLTFF vs JEPITLTFF vs OTLTFF vs KOTLTFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.